Avenue Therapeutics, the Compensation Committee of the Board, has approved equity awards to its executive officers, granting an option to purchase 800,000 shares to Alexandra MacLean, the Chief Executive Officer, and an option to purchase 250,000 shares to David Jin, the Interim Principal Financial Officer and Chief Operating Officer. The options, with an exercise price of $1.14 per share, will vest in four equal annual installments starting on August 1, 2023, given the officers continue to serve the Company.